FeesSafety
Pluang+

Broadridge Q1 FY27 recurring revenue up 11%, adjusted EPS rises 3%, reaffirms full-year guidance.

Company Fundamentals
03 Nov 2026, 14:00 WIB
PRNewsWire
View Source
Bullish
Broadridge Q1 FY27 recurring revenue up 11%, adjusted EPS rises 3%, reaffirms full-year guidance.

Broadridge Financial Solutions reported an 11% increase in recurring revenues and a 3% rise in adjusted EPS to $1.56 for Q1 FY27, driven by organic growth and acquisitions. Closed sales grew 10% to $36 million, while total revenues increased 5%. Despite a 41% drop in GAAP diluted EPS due to non-operating losses, the company reaffirmed its FY27 guidance, expecting 6-8% recurring revenue growth, 8-12% adjusted EPS growth, and closed sales between $290-$330 million. Broadridge continues to invest in digital engagement, AI, and tokenization, with strong cash flow and shareholder returns through buybacks and dividends.

Broadridge Financial Solutions reported an 11% increase in recurring revenues and a 3% rise in adjusted EPS for Q1 FY27, highlighting its ongoing growth efforts. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 03, 2026 18:42 WIB: out of 142 priced US Financials stocks, 56 rose and 77 fell. Notable movers include Carlyle Group Inc (CG) at USD 40.20 with a -2.09% change and a typical hold time of 112 days, Hut 8 Corp (HUT) at USD 56.00 with a +1.81% change and 100% sell order activity, and Gemini Space Station Inc (GEMI) at USD 2.70 with a +1.69% change and 100% sell order activity.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
2 hours ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
2 hours ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
2 hours ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
3 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App